<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90700">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01883453</url>
  </required_header>
  <id_info>
    <org_study_id>GOcoldU&amp;B2013</org_study_id>
    <nct_id>NCT01883453</nct_id>
  </id_info>
  <brief_title>A Nasal Spray With Glucose Oxidase as a Treatment of Common Cold</brief_title>
  <official_title>A Double Blinded Clinical Study Aiming to Shorten an Episode of Common Cold When the Treatment is Started at the Onset of an Episode of Common Cold</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <authority>Sweden: Regional Committee of Ethics</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy persons are invited to participate in the study and are given a home protocol
      (WURSS21), nasal spray and a sample pin. The included persons are told to make a
      nasopharyngeal sampling from the nose when they are sure that they have caught a common
      cold. After the sampling they start to spray and also fill in the records daily. The aim of
      the study is to investigate whether a nasal spray with glucose oxidase could shorten an
      episode of common cold.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reducing symptoms of a common cold</measure>
    <time_frame>One week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Using the Wisconsin Upper Respiratory Symptom Score (WURSS-21)it is possible to assess if a nasal spray containing glucose oxidase and glucose would be able to reduce symptoms of a common cold</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Reducing Symptoms of a Common Cold</condition>
  <arm_group>
    <arm_group_label>Saline+glucose nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A nasal spray with isotone saline + 5% glucose, dosing one puff 5 times daily in each nostril at the first treatment day and thereafter trice daily for a total of one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal spray with glucose oxidase+glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A nasal spray with 200U/ml of glucose oxidase + 5% glucose. Treatment starts with 5 puffs in each nostril at the first day, and thereafter trhee times daily for a total treatment time of one week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose oxidase+glucose</intervention_name>
    <description>A hydrogen peroxide producing enzyme</description>
    <arm_group_label>Nasal spray with glucose oxidase+glucose</arm_group_label>
    <other_name>Nasal spray containing saline solution+glucose oxidase+5%glucose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline+glucose</intervention_name>
    <description>Isotonic saline + 5% glucose in a bag-on-valve nasal spray device</description>
    <arm_group_label>Saline+glucose nasal spray</arm_group_label>
    <other_name>Nasal spray with isotonic saline + 5% glucose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults

        Exclusion Criteria:

          -  Ongoing allergy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krister Tano, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krister Tano, MD, PhD</last_name>
    <phone>00465569043</phone>
    <email>krister.tano@nll.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Försvarshälsan</name>
      <address>
        <city>Boden</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liselott Tano, MD</last_name>
      <email>liselott.tano@mil.se</email>
    </contact>
    <investigator>
      <last_name>Liselott Tano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Idrottsmedicin</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christer Malm, Associate professor</last_name>
      <email>christer.malm@idrott.umu.se</email>
    </contact>
    <investigator>
      <last_name>Christer Malm, Associate professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 24, 2013</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Umeå University</investigator_affiliation>
    <investigator_full_name>Krister Tano</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
